# Adversarial verification verdict: hereditary_leiomyomatosis_renal_cell_cancer

1. DOSE LEAK: none. No mg, mg/m2, AUC, or numbered cycle/schedule anywhere in the sidecar. The only
   numeral-bearing clinical term is "3 cm rule" (a tumor-size staging/surveillance threshold, not a
   dose), and it is directly attested in DeVita Table 43.1 ("Generally poor prognosis, so early
   treatment is recommended (exception to the 3 cm rule)") — confirmed by grep at devita.txt line
   ~149035.

2. UNGROUNDED CLAIMS: none found unlabeled. Every claim beyond the two DeVita-attested facts below is
   explicitly tagged "(general oncology standard, not from DeVita's section on this disease)":
   - bevacizumab + erlotinib for metastatic FH-deficient RCC — correctly flagged as NOT DeVita-HLRCC;
     verified that DeVita's own bevacizumab+erlotinib passages are in the hepatocellular carcinoma
     chapter (devita.txt line ~111416, RR 24%/OS 13.7mo vs sorafenib) and the CUP chapter (line
     ~290789), neither is HLRCC. The sidecar's disclaimer is accurate and the sidecar does not import
     those HCC/CUP statistics as if HLRCC-specific.
   - Cutaneous/uterine leiomyoma management, MRI-specific surveillance, genetic-counseling referral,
     surgery-as-mainstay for localized disease, standard clear-cell TKI/IO non-applicability — all
     correctly tagged as general standard, none presented as DeVita sourcing.
   Two claims ARE genuinely DeVita-grounded and correctly presented as such (verified independently):
   - "exception to the 3 cm rule" / early treatment recommended — Table 43.1, devita.txt ~149035.
   - "unilateral and solitary... early age of onset... aggressive, metastasize, and cause death within
     5 years of diagnosis" — DeVita narrative text, devita.txt lines 150122-150125 (verbatim match).
   No fabricated trial names, NCT numbers, or invented statistics were introduced.

3. CITATION: present — "Sources: DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of
   Oncology, 12th ed." (name only, no page numbers). Correct.

4. VERDICT: CLEAN — ready for R1. No dose leak, no unlabeled fabrication; the sidecar is unusually
   careful to distinguish its two genuine DeVita citations (3 cm rule exception; 5-year mortality/early
   onset/unilateral-solitary language) from everything else, which it consistently and correctly labels
   as general-oncology-standard rather than DeVita-sourced.
